好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Myelopathies Secondary to Sjogren Syndrome: Potential Interest of Treatment with Intravenous Cyclophosphamide
Neurotoxicology
(-)
170
Authors/Disclosures
Weredes Olango, MD (WellStar Health System) No disclosure on file
Zabeen K. Mahuwala, MD, FAAN (University of Kentucky, KY Clinic Neurology Department) Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for academic CME. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Scientific affairs. Dr. Mahuwala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for amgen. The institution of Dr. Mahuwala has received research support from UCB, . The institution of Dr. Mahuwala has received research support from Alexion . The institution of Dr. Mahuwala has received research support from argenx . The institution of Dr. Mahuwala has received research support from immunovant.
Hiroki Nariai, MD (UCLA Mattel Children's Hospital) Dr. Nariai has nothing to disclose.
Weredes Olango, MD (WellStar Health System) No disclosure on file
Weredes Olango, MD (WellStar Health System) No disclosure on file
Weredes Olango, MD (WellStar Health System) No disclosure on file
Weredes Olango, MD (WellStar Health System) No disclosure on file
Weredes Olango, MD (WellStar Health System) No disclosure on file